Fig. 2

S100A4 silencing inhibits activation markers of ALS fibroblasts. Fibroblasts from ALS patients with no known ALS variants (uvALS) and C9orf72 ALS patients were treated with S100A4 siRNA and scrambled siRNA (Scr) and then harvested after 72 h of transfection. a Protein lysates of uvALS fibroblasts were subjected to western blot using anti-S100A4, anti-mTOR, anti-SQSTM1/p62. GAPDH was used to normalize samples. Values are mean ± SEM, n = 3 individuals, experiments repeated in triplicate; two-tailed t test. t value: 5.037, degrees of freedom: 4 (S100A4); t value: 3.141, degrees of freedom: 4 (mTOR); t value: 4.630, degrees of freedom: 4 (SQSTM1/p62). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. scrambled siRNA. b Protein lysates of C9orf72 fibroblasts were subjected to western blot using anti-S100A4, anti-mTOR, anti-SQSTM1/p62, anti-NF-κB, and anti-p-NF-κB. GAPDH was used to normalize samples. Values are mean ± SEM, n = 3 individuals, experiments repeated in triplicate; two-tailed t test. t value: 6.476, degrees of freedom: 4 (S100A4); t value: 5.183, degrees of freedom: 4 (mTOR); t value: 8.708, degrees of freedom: 4 (SQSTM1/p62); two-tailed t test with Welch’s correction. t value: 5.407, degrees of freedom: 2.053 (p-NFκB/NFκb). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. scrambled siRNA